{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:58:01Z","timestamp":1793228281867,"version":"4.5.0"},"reference-count":346,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02572-2","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:35:24Z","timestamp":1770024924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tumor microenvironment dynamics in gastric cancer pathogenesis and therapeutic resistance"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhenhua","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"3","key":"2572_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2572_CR2","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1016\/j.cgh.2020.04.085","volume":"18","author":"MK Pourmousavi","year":"2020","unstructured":"Pourmousavi MK, Wang R, Kerdsirichairat T, et al. Comparable cancer-specific mortality of patients with early gastric cancer treated with endoscopic therapy vs surgical resection. Clin Gastroenterol Hepatol. 2020;18(12):2824-2832.e2821.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2572_CR3","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S1470-2045(24)00180-3","volume":"25","author":"M Svrcek","year":"2024","unstructured":"Svrcek M, Voron T, Andr\u00e9 T, Smyth EC, de la Fouchardi\u00e8re C. Improving individualised therapies in localised gastro-oesophageal adenocarcinoma. Lancet Oncol. 2024;25(9):e452-63.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2572_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10120-024-01523-4","volume":"27","author":"A Ooki","year":"2024","unstructured":"Ooki A, Osumi H, Yoshino K, Yamaguchi K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair. Gastric Cancer. 2024;27(5):907\u201331.","journal-title":"Gastric Cancer"},{"issue":"2","key":"2572_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2572_CR6","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482\u201392.","journal-title":"Ann Oncol"},{"issue":"1","key":"2572_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-024-01937-7","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang Y, Jia J, Wang F, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Signal Transduct Target Ther. 2024;9(1):236.","journal-title":"Signal Transduct Target Ther"},{"key":"2572_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116317","volume":"172","author":"B Wang","year":"2024","unstructured":"Wang B, Song B, Li Y, Zhao Q, Tan B. Mapping spatial heterogeneity in gastric cancer microenvironment. Biomed Pharmacother. 2024;172:116317.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"2572_CR9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41575-022-00669-9","volume":"19","author":"N Vaes","year":"2022","unstructured":"Vaes N, Idris M, Boesmans W, Alves MM, Melotte V. Nerves in gastrointestinal cancer: from mechanism to modulations. Nat Rev Gastroenterol Hepatol. 2022;19(12):768\u201384.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"2572_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-023-01723-x","volume":"9","author":"Z Hu","year":"2024","unstructured":"Hu Z, Zhao X, Wu Z, et al. Lymphatic vessel: origin, heterogeneity, biological functions, and therapeutic targets. Signal Transduct Target Ther. 2024;9(1):9.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2572_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ng.2983","volume":"46","author":"K Wang","year":"2014","unstructured":"Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573\u201382.","journal-title":"Nat Genet"},{"key":"2572_CR12","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1007\/s13277-015-4002-1","volume":"36","author":"Y Lin","year":"2015","unstructured":"Lin Y, Wu Z, Guo W, Li J. Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. Tumor Biol. 2015;36:7385\u201394.","journal-title":"Tumor Biol"},{"issue":"5","key":"2572_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4132\/jptm.2020.06.01","volume":"54","author":"HJ Hwang","year":"2020","unstructured":"Hwang HJ, Nam SK, Park H, et al. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer. J Pathol Transl Med. 2020;54(5):378\u201386.","journal-title":"J Pathol Transl Med"},{"issue":"3","key":"2572_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/humu.10180","volume":"21","author":"CM Fenoglio-Preiser","year":"2003","unstructured":"Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat. 2003;21(3):258\u201370.","journal-title":"Hum Mutat"},{"issue":"5","key":"2572_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.tranon.2018.07.012","volume":"11","author":"Z Jiang","year":"2018","unstructured":"Jiang Z, Liu Z, Li M, Chen C, Wang X. Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer. Transl Oncol. 2018;11(5):1171\u201387.","journal-title":"Transl Oncol"},{"issue":"12","key":"2572_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1089\/ars.2020.8074","volume":"33","author":"T Shi","year":"2020","unstructured":"Shi T, Dansen TB. Reactive oxygen species induced p53 activation: DNA damage, redox signaling, or both? Antioxid Redox Signal. 2020;33(12):839\u201359.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"2572_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","volume":"21","author":"HE Marei","year":"2021","unstructured":"Marei HE, Althani A, Afifi N, et al. P53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"2572_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103452","volume":"21","author":"AD Agupitan","year":"2020","unstructured":"Agupitan AD, Neeson P, Williams S, Howitt J, Haupt S, Haupt Y. P53: a guardian of immunity becomes its saboteur through mutation. Int J Mol Sci. 2020;21(10):3452.","journal-title":"Int J Mol Sci"},{"issue":"46","key":"2572_CR19","doi-asserted-by":"publisher","first-page":"E10869","DOI":"10.1073\/pnas.1808314115","volume":"115","author":"I Amelio","year":"2018","unstructured":"Amelio I, Mancini M, Petrova V, et al. P53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci U S A. 2018;115(46):E10869\u201378.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2572_CR20","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-13-3608","volume":"74","author":"R Watanabe","year":"2014","unstructured":"Watanabe R, Ui A, Kanno S-i, et al. SWI\/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability. Cancer Res. 2014;74(9):2465\u201375.","journal-title":"Cancer Res"},{"issue":"12","key":"2572_CR21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/ng.982","volume":"43","author":"K Wang","year":"2011","unstructured":"Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219\u201323.","journal-title":"Nat Genet"},{"key":"2572_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00428-012-1303-2","volume":"461","author":"H Abe","year":"2012","unstructured":"Abe H, Maeda D, Hino R, et al. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch. 2012;461:367\u201377.","journal-title":"Virchows Arch"},{"issue":"9","key":"2572_CR23","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1136\/gutjnl-2022-328332","volume":"72","author":"C Xu","year":"2023","unstructured":"Xu C, Huang KK, Law JH, et al. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut. 2023;72(9):1651\u201363.","journal-title":"Gut"},{"issue":"4","key":"2572_CR24","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/ijc.32140","volume":"145","author":"YB Kim","year":"2019","unstructured":"Kim YB, Ahn JM, Bae WJ, Sung CO, Lee D. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019;145(4):916\u201326.","journal-title":"Int J Cancer"},{"issue":"6","key":"2572_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4161\/cbt.28411","volume":"15","author":"R-C Wu","year":"2014","unstructured":"Wu R-C, Wang T-L, Shih I-M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014;15(6):655\u201364.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2572_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/gutjnl-2020-322660","volume":"71","author":"X Dong","year":"2022","unstructured":"Dong X, Song S, Li Y, et al. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut. 2022;71(3):467\u201378.","journal-title":"Gut"},{"key":"2572_CR27","doi-asserted-by":"publisher","first-page":"107499","DOI":"10.1016\/j.phrs.2024.107499","volume":"210","author":"F Ma","year":"2024","unstructured":"Ma F, Ren M, Li Z, et al. ARID1A is a coactivator of STAT5 that contributes to CD8(+) T cell dysfunction and anti-PD-1 resistance in gastric cancer. Pharmacol Res. 2024;210:107499.","journal-title":"Pharmacol Res"},{"issue":"11","key":"2572_CR28","first-page":"3947","volume":"10","author":"J Zou","year":"2020","unstructured":"Zou J, Qin W, Yang L, et al. Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. Am J Cancer Res. 2020;10(11):3947\u201372.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2572_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13148-024-01805-9","volume":"17","author":"Y Tang","year":"2025","unstructured":"Tang Y, Zhang R, Mao G, et al. Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation. Clin Epigenetics. 2025;17(1):2.","journal-title":"Clin Epigenetics"},{"issue":"5","key":"2572_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","volume":"61","author":"N Deng","year":"2012","unstructured":"Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673\u201384.","journal-title":"Gut"},{"key":"2572_CR31","doi-asserted-by":"publisher","first-page":"1567308","DOI":"10.3389\/fimmu.2025.1567308","volume":"16","author":"J Yao","year":"2025","unstructured":"Yao J, Sun Q, Wu H, et al. Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer. Front Immunol. 2025;16:1567308.","journal-title":"Front Immunol"},{"issue":"2","key":"2572_CR32","first-page":"111","volume":"23","author":"O Abidoye","year":"2025","unstructured":"Abidoye O, Hoyek C, Bekaii-Saab T. Targeting RAS in gastrointestinal malignancies. Clin Adv Hematol Oncol. 2025;23(2):111\u201322.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"2572_CR33","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.21037\/jgo-20-617","volume":"12","author":"N Wu","year":"2021","unstructured":"Wu N, Huang Y, Liu F, Xu X, Liu B, Wei J. KRAS gene status in gastric signet-ring cell carcinoma patients and acts as biomarker of MEK inhibitor. J Gastrointest Oncol. 2021;12(3):1020\u201330.","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"2572_CR34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30(4):969\u201383.","journal-title":"Nat Med"},{"key":"2572_CR35","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S208818","author":"S Shenoy","year":"2019","unstructured":"Shenoy S. CDH1 (E-cadherin) mutation and gastric cancer: genetics, molecular mechanisms and guidelines for management. Cancer Manag Res. 2019. https:\/\/doi.org\/10.2147\/CMAR.S208818.","journal-title":"Cancer Manag Res"},{"issue":"7517","key":"2572_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Research Network Cancer Genome Atlas","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"21","key":"2572_CR37","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1001\/jama.297.21.2360","volume":"297","author":"P Kaurah","year":"2007","unstructured":"Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297(21):2360\u201372.","journal-title":"JAMA"},{"issue":"1","key":"2572_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13046-023-02622-3","volume":"42","author":"HJ Lim","year":"2023","unstructured":"Lim HJ, Zhuang L, Fitzgerald RC. Current advances in understanding the molecular profile of hereditary diffuse gastric cancer and its clinical implications. J Exp Clin Cancer Res. 2023;42(1):57.","journal-title":"J Exp Clin Cancer Res"},{"key":"2572_CR39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230561","author":"G Zou","year":"2024","unstructured":"Zou G, Huang Y, Zhang S, et al. E-cadherin loss drives diffuse-type gastric tumorigenesis via EZH2-mediated reprogramming. J Exp Med. 2024. https:\/\/doi.org\/10.1084\/jem.20230561.","journal-title":"J Exp Med"},{"issue":"1","key":"2572_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01052-y","volume":"9","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Li J. Immunotherapy for diffuse gastric cancer: challenges and new avenues. NPJ Precis Oncol. 2025;9(1):247.","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"2572_CR41","doi-asserted-by":"publisher","first-page":"e97306","DOI":"10.1371\/journal.pone.0097306","volume":"9","author":"W Xu","year":"2014","unstructured":"Xu W, Hu X, Chen Z, et al. Normal fibroblasts induce E-cadherin loss and increase lymph node metastasis in gastric cancer. PLoS One. 2014;9(5):e97306.","journal-title":"PLoS One"},{"issue":"12","key":"2572_CR42","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/1541-7786.MCR-23-0122","volume":"21","author":"BL Green","year":"2023","unstructured":"Green BL, Gamble LA, Diggs LP, et al. Early immune changes support signet ring cell dormancy in CDH1-driven hereditary diffuse gastric carcinogenesis. Mol Cancer Res. 2023;21(12):1356\u201365.","journal-title":"Mol Cancer Res"},{"key":"2572_CR43","doi-asserted-by":"publisher","first-page":"103841","DOI":"10.1016\/j.critrevonc.2022.103841","volume":"181","author":"MJ L\u00f3pez","year":"2023","unstructured":"L\u00f3pez MJ, Carbajal J, Alfaro AL, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol. 2023;181:103841.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Pt 1","key":"2572_CR44","doi-asserted-by":"publisher","first-page":"133247","DOI":"10.1016\/j.ijbiomac.2024.133247","volume":"274","author":"RR Malla","year":"2024","unstructured":"Malla RR, Nellipudi HR, Srilatha M, Nagaraju GP. Her-2 positive gastric cancer: current targeted treatments. Int J Biol Macromol. 2024;274(Pt 1):133247.","journal-title":"Int J Biol Macromol"},{"key":"2572_CR45","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5624","author":"HH Hu","year":"2024","unstructured":"Hu HH, Wang SQ, Zhao H, Chen ZS, Shi X, Chen XB. HER2(+) advanced gastric cancer: current state and opportunities (Review). Int J Oncol. 2024. https:\/\/doi.org\/10.3892\/ijo.2024.5624.","journal-title":"Int J Oncol"},{"issue":"1","key":"2572_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"2572_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10120-017-0739-0","volume":"21","author":"JS Park","year":"2018","unstructured":"Park JS, Lee N, Beom SH, et al. The prognostic value of volume-based parameters using (18)F-FDG PET\/CT in gastric cancer according to HER2 status. Gastric Cancer. 2018;21(2):213\u201324.","journal-title":"Gastric Cancer"},{"issue":"5","key":"2572_CR48","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41416-022-01834-2","volume":"127","author":"X Yao","year":"2022","unstructured":"Yao X, He Z, Qin C, et al. Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation. Br J Cancer. 2022;127(5):811\u201323.","journal-title":"Br J Cancer"},{"issue":"8","key":"2572_CR49","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1158\/0008-5472.CAN-21-1820","volume":"82","author":"J Wang","year":"2022","unstructured":"Wang J, Huang Q, Hu X, et al. Disrupting circadian rhythm via the PER1-HK2 axis reverses trastuzumab resistance in gastric cancer. Cancer Res. 2022;82(8):1503\u201317.","journal-title":"Cancer Res"},{"issue":"24","key":"2572_CR50","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.3390\/cancers13246158","volume":"13","author":"J Chakrabarti","year":"2021","unstructured":"Chakrabarti J, Koh V, Steele N, et al. Disruption of Her2-induced PD-L1 inhibits tumor cell immune evasion in patient-derived gastric cancer organoids. Cancers (Basel). 2021;13(24):6158.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2572_CR51","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.canlet.2013.08.016","volume":"345","author":"F Wang","year":"2014","unstructured":"Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014;345(2):196\u2013202.","journal-title":"Cancer Lett"},{"issue":"1","key":"2572_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1751-2980.2011.00550.x","volume":"13","author":"P Correa","year":"2012","unstructured":"Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13(1):2\u20139.","journal-title":"J Dig Dis"},{"issue":"6","key":"2572_CR53","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2023.08.028","volume":"165","author":"K Sugano","year":"2023","unstructured":"Sugano K, Moss SF, Kuipers EJ. Gastric intestinal metaplasia: real culprit or innocent bystander as a precancerous condition for gastric cancer? Gastroenterology. 2023;165(6):1352-1366.e1351.","journal-title":"Gastroenterology"},{"key":"2572_CR54","doi-asserted-by":"publisher","first-page":"106440","DOI":"10.1016\/j.phrs.2022.106440","volume":"184","author":"Q Liu","year":"2022","unstructured":"Liu Q, Tang J, Chen S, et al. Berberine for gastric cancer prevention and treatment: multi-step actions on the Correa\u2019s cascade underlie its therapeutic effects. Pharmacol Res. 2022;184:106440.","journal-title":"Pharmacol Res"},{"key":"2572_CR55","doi-asserted-by":"publisher","first-page":"115191","DOI":"10.1016\/j.intimp.2025.115191","volume":"162","author":"J Zhou","year":"2025","unstructured":"Zhou J, Li J, Chen J, et al. Decoding inflammatory mediators in the Correa\u2019s cascade: from chronic gastritis to carcinogenesis and targeted therapies. Int Immunopharmacol. 2025;162:115191.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2572_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01654-2","volume":"18","author":"Y Duan","year":"2025","unstructured":"Duan Y, Xu Y, Dou Y, Xu D. Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol. 2025;18(1):10.","journal-title":"J Hematol Oncol"},{"issue":"38","key":"2572_CR57","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.2174\/138161210794519075","volume":"16","author":"P Ruggiero","year":"2010","unstructured":"Ruggiero P. Helicobacter pylori and inflammation. Curr Pharm Des. 2010;16(38):4225\u201336.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2572_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41423-019-0339-5","volume":"17","author":"A Takahashi-Kanemitsu","year":"2020","unstructured":"Takahashi-Kanemitsu A, Knight CT, Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell Mol Immunol. 2020;17(1):50\u201363.","journal-title":"Cell Mol Immunol"},{"key":"2572_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1633227","volume":"15","author":"H Xin","year":"2025","unstructured":"Xin H, Zhu C, Zhu C, Zhang X, Chen D, Wang Q. Beyond the stomach: the association between Helicobacter pylori and the spectrum of digestive cancers. Front Cell Infect Microbiol. 2025;15:1633227.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"2572_CR60","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1128\/IAI.01370-10","volume":"79","author":"JN Radin","year":"2011","unstructured":"Radin JN, Gonz\u00e1lez-Rivera C, Ivie SE, McClain MS, Cover TL. Helicobacter pylori VacA induces programmed necrosis in gastric epithelial cells. Infect Immun. 2011;79(7):2535\u201343.","journal-title":"Infect Immun"},{"key":"2572_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032895","author":"S Salvatori","year":"2023","unstructured":"Salvatori S, Marafini I, Laudisi F, Monteleone G, Stolfi C. Helicobacter pylori and gastric cancer: pathogenetic mechanisms. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24032895.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2572_CR62","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12964-024-02017-7","volume":"23","author":"X Fei","year":"2025","unstructured":"Fei X, Chen S, Li L, et al. Helicobacter pylori infection promotes M1 macrophage polarization and gastric inflammation by activation of NLRP3 inflammasome via TNF\/TNFR1 axis. Cell Commun Signal. 2025;23(1):6.","journal-title":"Cell Commun Signal"},{"issue":"10\u201312","key":"2572_CR63","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00011-021-01501-x","volume":"70","author":"H Yang","year":"2021","unstructured":"Yang H, Wei B, Hu B. Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer. Inflamm Res. 2021;70(10\u201312):1015\u201326.","journal-title":"Inflamm Res"},{"issue":"3","key":"2572_CR64","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jcb.24389","volume":"114","author":"A Lamb","year":"2013","unstructured":"Lamb A, Chen LF. Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cancer. J Cell Biochem. 2013;114(3):491\u20137.","journal-title":"J Cell Biochem"},{"issue":"4","key":"2572_CR65","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/cas.12901","volume":"107","author":"K Echizen","year":"2016","unstructured":"Echizen K, Hirose O, Maeda Y, Oshima M. Inflammation in gastric cancer: interplay of the COX-2\/prostaglandin E2 and Toll-like receptor\/MyD88 pathways. Cancer Sci. 2016;107(4):391\u20137.","journal-title":"Cancer Sci"},{"key":"2572_CR66","doi-asserted-by":"crossref","unstructured":"Rasch S, Alg\u00fcl H. A clinical perspective on the role of chronic inflammation in gastrointestinal cancer. Clin Exp Gastroenterol. 2014:261-272.","DOI":"10.2147\/CEG.S43457"},{"issue":"1","key":"2572_CR67","first-page":"42","volume":"1869","author":"MC Mommersteeg","year":"2018","unstructured":"Mommersteeg MC, Yu J, Peppelenbosch MP, Fuhler GM. Genetic host factors in Helicobacter pylori-induced carcinogenesis: emerging new paradigms. Biochimica et Biophysica Acta (BBA). 2018;1869(1):42\u201352.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"3","key":"2572_CR68","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/febs.13578","volume":"283","author":"L D\u2019Ignazio","year":"2016","unstructured":"D\u2019Ignazio L, Bandarra D, Rocha S. NF-\u03baB and HIF crosstalk in immune responses. FEBS J. 2016;283(3):413\u201324.","journal-title":"FEBS J"},{"key":"2572_CR69","doi-asserted-by":"crossref","unstructured":"Navashenaq JG, Shabgah AG, Banach M, et al. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: new insight into gastric cancer pathogenesis. 2022.","DOI":"10.1016\/j.semcancer.2021.09.014"},{"issue":"1","key":"2572_CR70","volume":"2010","author":"A Szkaradkiewicz","year":"2010","unstructured":"Szkaradkiewicz A, Karpi\u0144ski TM, Drews M, Borejsza-Wysocki M, Majewski P, Andrzejewska E. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-\u03b21) in patients with gastric cancer. Biomed Res Int. 2010;2010(1):901564.","journal-title":"Biomed Res Int"},{"issue":"2","key":"2572_CR71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3181\/0808-RM-252","volume":"234","author":"Y-H Wang","year":"2009","unstructured":"Wang Y-H, Wu J-J, Lei H-Y. The autophagic induction in Helicobacter pylori-infected macrophage. Exp Biol Med. 2009;234(2):171\u201380.","journal-title":"Exp Biol Med"},{"issue":"1","key":"2572_CR72","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pbj.2016.03.004","volume":"1","author":"R Silva","year":"2016","unstructured":"Silva R, Gullo I, Carneiro F. The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: a comprehensive review and future perspectives. Porto Biomed J. 2016;1(1):4\u201311.","journal-title":"Porto Biomed J"},{"key":"2572_CR73","doi-asserted-by":"publisher","first-page":"1591735","DOI":"10.3389\/fmicb.2025.1591735","volume":"16","author":"X Lv","year":"2025","unstructured":"Lv X, Song P, Zhang N, et al. Live bacteria found in gastric cancer tumor tissue. Front Microbiol. 2025;16:1591735.","journal-title":"Front Microbiol"},{"key":"2572_CR74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.canlet.2017.11.009","volume":"414","author":"JL Espinoza","year":"2018","unstructured":"Espinoza JL, Matsumoto A, Tanaka H, Matsumura I. Gastric microbiota: an emerging player in Helicobacter pylori-induced gastric malignancies. Cancer Lett. 2018;414:147\u201352.","journal-title":"Cancer Lett"},{"issue":"1","key":"2572_CR75","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41698-025-00810-2","volume":"9","author":"H Wang","year":"2025","unstructured":"Wang H, You W, Zhu Z, et al. Streptococcus lutetiensis inhibits CD8(+) IL17A(+) TRM cells and leads to gastric cancer progression and poor prognosis. NPJ Precis Oncol. 2025;9(1):43.","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"2572_CR76","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/gutjnl-2017-314205","volume":"67","author":"RM Ferreira","year":"2018","unstructured":"Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67(2):226\u201336.","journal-title":"Gut"},{"issue":"2","key":"2572_CR77","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2478\/raon-2024-0028","volume":"58","author":"J Drnovsek","year":"2024","unstructured":"Drnovsek J, Homan M, Zidar N, Smid LM. Pathogenesis and potential reversibility of intestinal metaplasia - a milestone in gastric carcinogenesis. Radiol Oncol. 2024;58(2):186\u201395.","journal-title":"Radiol Oncol"},{"issue":"6","key":"2572_CR78","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/ijc.33848","volume":"150","author":"F Wu","year":"2022","unstructured":"Wu F, Yang L, Hao Y, et al. Oral and gastric microbiome in relation to gastric intestinal metaplasia. Int J Cancer. 2022;150(6):928\u201340.","journal-title":"Int J Cancer"},{"issue":"4","key":"2572_CR79","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.cell.2024.01.004","volume":"187","author":"K Fu","year":"2024","unstructured":"Fu K, Cheung AHK, Wong CC, et al. Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell. 2024;187(4):882-896.e817.","journal-title":"Cell"},{"issue":"5","key":"2572_CR80","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00430-018-0570-1","volume":"208","author":"H Yin","year":"2019","unstructured":"Yin H, Qu J, Peng Q, Gan R. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med Microbiol Immunol. 2019;208(5):573\u201383.","journal-title":"Med Microbiol Immunol"},{"key":"2572_CR81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2020.09.019","volume":"495","author":"J Yang","year":"2020","unstructured":"Yang J, Liu Z, Zeng B, Hu G, Gan R. Epstein-Barr virus-associated gastric cancer: a distinct subtype. Cancer Lett. 2020;495:191\u20139.","journal-title":"Cancer Lett"},{"key":"2572_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010074","author":"CN do Nascimento","year":"2022","unstructured":"do Nascimento CN, Mascarenhas-Lemos L, Silva JR, et al. EBV and MSI status in gastric cancer: does it matter? Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers15010074.","journal-title":"Cancers"},{"issue":"5","key":"2572_CR83","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10120-021-01215-3","volume":"24","author":"M Saito","year":"2021","unstructured":"Saito M, Kono K. Landscape of EBV-positive gastric cancer. Gastric Cancer. 2021;24(5):983\u20139.","journal-title":"Gastric Cancer"},{"issue":"51","key":"2572_CR84","doi-asserted-by":"publisher","first-page":"E12005","DOI":"10.1073\/pnas.1815660115","volume":"115","author":"D Zella","year":"2018","unstructured":"Zella D, Curreli S, Benedetti F, et al. Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties. Proc Natl Acad Sci U S A. 2018;115(51):E12005-e12014.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2572_CR85","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3748\/wjg.v7.i2.266","volume":"7","author":"S Huang","year":"2001","unstructured":"Huang S, Li JY, Wu J, Meng L, Shou CC. Mycoplasma infections and different human carcinomas. World J Gastroenterol. 2001;7(2):266\u20139.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2572_CR86","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13027-021-00410-2","volume":"16","author":"CD Nascimento Araujo","year":"2021","unstructured":"Nascimento Araujo CD, Amorim AT, Barbosa MS, et al. Evaluating the presence of Mycoplasma hyorhinis, Fusobacterium nucleatum, and Helicobacter pylori in biopsies of patients with gastric cancer. Infect Agents Cancer. 2021;16(1):70.","journal-title":"Infect Agents Cancer"},{"issue":"11","key":"2572_CR87","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1002\/cam4.2357","volume":"8","author":"X Liu","year":"2019","unstructured":"Liu X, Rong Z, Shou C. Mycoplasma hyorhinis infection promotes gastric cancer cell motility via \u03b2-catenin signaling. Cancer Med. 2019;8(11):5301\u201312.","journal-title":"Cancer Med"},{"key":"2572_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-10-132","volume":"10","author":"H Yang","year":"2010","unstructured":"Yang H, Qu L, Ma H, et al. <Text>Mycoplasma hyorhinis infection in gastric carcinoma and its effects on the malignant phenotypes of gastric cancer cells<\/Text>. BMC Gastroenterol. 2010;10:132.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"2572_CR89","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.canlet.2014.08.018","volume":"354","author":"H Duan","year":"2014","unstructured":"Duan H, Qu L, Shou C. Mycoplasma hyorhinis induces epithelial-mesenchymal transition in gastric cancer cell MGC803 via TLR4-NF-\u03baB signaling. Cancer Lett. 2014;354(2):447\u201354.","journal-title":"Cancer Lett"},{"issue":"1","key":"2572_CR90","volume":"1","author":"A Bates","year":"2025","unstructured":"Bates A, Fletcher NE, Gao F, Pereira Pinho M, Dong TJI. Leveraging T cells for cancer immunotherapy. Inflammation. 2025;1(1):9.","journal-title":"Inflammation"},{"key":"2572_CR91","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong C. Cytokine regulation and function in T cells. Annu Rev Immunol. 2021;39:51\u201376.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2572_CR92","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022;22(4):209\u201323.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2572_CR93","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nri3536","volume":"13","author":"V Lazarevic","year":"2013","unstructured":"Lazarevic V, Glimcher LH, Lord GM. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol. 2013;13(11):777\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2572_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58958-1","volume":"16","author":"S Tang","year":"2025","unstructured":"Tang S, Che X, Wang J, et al. T-bet(+)CD8(+) T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers. Nat Commun. 2025;16(1):3905.","journal-title":"Nat Commun"},{"issue":"10","key":"2572_CR95","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/ijc.23392","volume":"122","author":"Y Mizukami","year":"2008","unstructured":"Mizukami Y, Kono K, Kawaguchi Y, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008;122(10):2286\u201393.","journal-title":"Int J Cancer"},{"issue":"1","key":"2572_CR96","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1038\/s41467-022-32627-z","volume":"13","author":"K Sun","year":"2022","unstructured":"Sun K, Xu R, Ma F, et al. Scrna-seq of gastric tumor shows complex intercellular interaction with an alternative T cell exhaustion trajectory. Nat Commun. 2022;13(1):4943.","journal-title":"Nat Commun"},{"key":"2572_CR97","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cellimm.2017.01.001","volume":"313","author":"X Lu","year":"2017","unstructured":"Lu X, Yang L, Yao D, et al. Tumor antigen-specific CD8(+) T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer. Cell Immunol. 2017;313:43\u201351.","journal-title":"Cell Immunol"},{"issue":"1","key":"2572_CR98","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1915560","volume":"10","author":"K Jin","year":"2021","unstructured":"Jin K, Cao Y, Gu Y, et al. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. Oncoimmunology. 2021;10(1):1915560.","journal-title":"Oncoimmunology"},{"issue":"18","key":"2572_CR99","first-page":"e2413019","volume":"12","author":"G Zhang","year":"2025","unstructured":"Zhang G, Zhang X, Pan W, et al. Dissecting the spatial and single-cell transcriptomic architecture of cancer stem cell niche driving tumor progression in gastric cancer. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2025;12(18):e2413019.","journal-title":"Adv Sci (Weinheim, Baden-Wurttemberg, Germany)."},{"issue":"1","key":"2572_CR100","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13059-022-02828-2","volume":"23","author":"B Kang","year":"2022","unstructured":"Kang B, Camps J, Fan B, et al. Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment. Genome Biol. 2022;23(1):265.","journal-title":"Genome Biol"},{"issue":"1","key":"2572_CR101","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","volume":"8","author":"Y Hu","year":"2023","unstructured":"Hu Y, Hu Q, Li Y, et al. \u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy. Signal Transduct Target Ther. 2023;8(1):434.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2572_CR102","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12928","volume":"298","author":"CR Willcox","year":"2020","unstructured":"Willcox CR, Mohammed F, Willcox BE. The distinct MHC-unrestricted immunobiology of innate-like and adaptive-like human \u03b3\u03b4 T cell subsets-nature\u2019s CAR-T cells. Immunol Rev. 2020;298(1):25\u201346.","journal-title":"Immunol Rev"},{"key":"2572_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02186","volume":"11","author":"G Chabab","year":"2020","unstructured":"Chabab G, Barjon C, Bonnefoy N, Lafont V. Pro-tumor \u03b3\u03b4 T cells in human cancer: polarization, mechanisms of action, and implications for therapy. Front Immunol. 2020;11:2186.","journal-title":"Front Immunol"},{"key":"2572_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1119383","volume":"14","author":"M Liang","year":"2023","unstructured":"Liang M, Wang X, Cai D, Guan W, Shen X. Tissue-resident memory T cells in gastrointestinal tumors: turning immune desert into immune oasis. Front Immunol. 2023;14:1119383.","journal-title":"Front Immunol"},{"issue":"6695","key":"2572_CR105","doi-asserted-by":"publisher","first-page":"eadj4857","DOI":"10.1126\/science.adj4857","volume":"384","author":"J Ma","year":"2024","unstructured":"Ma J, Wu Y, Ma L, et al. A blueprint for tumor-infiltrating B cells across human cancers. Science. 2024;384(6695):eadj4857.","journal-title":"Science"},{"issue":"2","key":"2572_CR106","doi-asserted-by":"publisher","first-page":"e1054598","DOI":"10.1080\/2162402X.2015.1054598","volume":"5","author":"A Hennequin","year":"2016","unstructured":"Hennequin A, Derang\u00e8re V, Boidot R, et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology. 2016;5(2):e1054598.","journal-title":"Oncoimmunology"},{"key":"2572_CR107","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jss.2017.03.033","volume":"215","author":"C Sakimura","year":"2017","unstructured":"Sakimura C, Tanaka H, Okuno T, et al. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer. J Surg Res. 2017;215:74\u201382.","journal-title":"J Surg Res"},{"issue":"3","key":"2572_CR108","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00432-024-05672-y","volume":"150","author":"H Peng","year":"2024","unstructured":"Peng H, Wu X, Zhang C, et al. Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies. J Cancer Res Clin Oncol. 2024;150(3):153.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"2572_CR109","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman WH, Meylan M, Pupier G, Calvez A, Hernandez I, Saut\u00e8s-Fridman C. Tertiary lymphoid structures and B cells: an intratumoral immunity cycle. Immunity. 2023;56(10):2254\u201369.","journal-title":"Immunity"},{"issue":"1","key":"2572_CR110","doi-asserted-by":"publisher","first-page":"27499","DOI":"10.1038\/s41598-025-11887-x","volume":"15","author":"Y Fujiwara","year":"2025","unstructured":"Fujiwara Y, Kinoshita J, Shimada M, et al. Regulatory b cells drive immune evasion in the tumor microenvironment and are involved peritoneal metastasis in gastric cancer. Sci Rep. 2025;15(1):27499.","journal-title":"Sci Rep"},{"key":"2572_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113002","volume":"141","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang W, Liu Q, et al. CD19(+)CD73(+) B cells infiltration indicates poor prognosis and unfavorable responses to immunotherapy in gastric cancer. Int Immunopharmacol. 2024;141:113002.","journal-title":"Int Immunopharmacol"},{"key":"2572_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02089-2","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu J, Geng X, Hou J, Wu G. New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 2021;21:1\u20137.","journal-title":"Cancer Cell Int"},{"issue":"12","key":"2572_CR113","first-page":"557","volume":"31","author":"X-Q Pan","year":"2012","unstructured":"Pan X-Q. The mechanism of the anticancer function of M1 macrophages and their use in the clinic. Chin J Cancer. 2012;31(12):557.","journal-title":"Chin J Cancer"},{"key":"2572_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002045","author":"PM Marcovecchio","year":"2021","unstructured":"Marcovecchio PM, Thomas G, Salek-Ardakani S. CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-002045.","journal-title":"J Immunother Cancer"},{"key":"2572_CR115","doi-asserted-by":"publisher","first-page":"102015","DOI":"10.1016\/j.ctrv.2020.102015","volume":"86","author":"V Gambardella","year":"2020","unstructured":"Gambardella V, Castillo J, Tarazona N, et al. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat Rev. 2020;86:102015.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"2572_CR116","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41419-019-2131-y","volume":"10","author":"W Li","year":"2019","unstructured":"Li W, Zhang X, Wu F, et al. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 2019;10(12):918.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2572_CR117","first-page":"595","volume":"42","author":"L Chen","year":"2019","unstructured":"Chen L, Shi Y, Zhu X, et al. IL-10 secreted by cancer-associated macrophages regulates proliferation and invasion in gastric cancer cells via c-Met\/STAT3 signaling. Oncol Rep. 2019;42(2):595\u2013604.","journal-title":"Oncol Rep"},{"issue":"24","key":"2572_CR118","doi-asserted-by":"publisher","first-page":"e2309298","DOI":"10.1002\/advs.202309298","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang J, Shi H, et al. M2 tumor-associated macrophages-derived exosomal MALAT1 promotes glycolysis and gastric cancer progression. Adv Sci. 2024;11(24):e2309298.","journal-title":"Adv Sci"},{"issue":"4","key":"2572_CR119","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/15384101.2021.1878326","volume":"20","author":"X Yang","year":"2021","unstructured":"Yang X, Cai S, Shu Y, et al. Exosomal miR-487a derived from m2 macrophage promotes the progression of gastric cancer. Cell Cycle. 2021;20(4):434\u201344.","journal-title":"Cell Cycle"},{"key":"2572_CR120","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12885-015-1114-3","volume":"15","author":"CN Lin","year":"2015","unstructured":"Lin CN, Wang CJ, Chao YJ, Lai MD, Shan YS. The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression. BMC Cancer. 2015;15:128.","journal-title":"BMC Cancer"},{"issue":"1","key":"2572_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76298-w","volume":"14","author":"Z Su","year":"2024","unstructured":"Su Z, He Y, You L, Chen J, Zhang G, Liu Z. SPP1+ macrophages and FAP+ fibroblasts promote the progression of pMMR gastric cancer. Sci Rep. 2024;14(1):26221.","journal-title":"Sci Rep"},{"issue":"1","key":"2572_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04688-1","volume":"22","author":"Y Du","year":"2024","unstructured":"Du Y, Lin Y, Gan L, et al. Potential crosstalk between SPP1 + TAMs and CD8 + exhausted T cells promotes an immunosuppressive environment in gastric metastatic cancer. J Transl Med. 2024;22(1):158.","journal-title":"J Transl Med"},{"key":"2572_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.953283","volume":"12","author":"Y Tan","year":"2022","unstructured":"Tan Y, Zhao L, Yang YG, Liu W. The role of Osteopontin in tumor progression through tumor-associated macrophages. Front Oncol. 2022;12:953283.","journal-title":"Front Oncol"},{"key":"2572_CR124","doi-asserted-by":"crossref","unstructured":"Gu Y, Muller WJ. The multifaceted role of osteopontin in modulating the tumor microenvironment. Cancer Res. 2025.","DOI":"10.1158\/0008-5472.c.8126103"},{"key":"2572_CR125","doi-asserted-by":"publisher","first-page":"114906","DOI":"10.1016\/j.intimp.2025.114906","volume":"160","author":"L Hou","year":"2025","unstructured":"Hou L, Jiang M, Li Y, et al. Targeting SPP1(+) macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer. Int Immunopharmacol. 2025;160:114906.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2572_CR126","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3\u20138.","journal-title":"Cancer Immunol Res"},{"key":"2572_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02499","volume":"9","author":"K Ohl","year":"2018","unstructured":"Ohl K, Tenbrock K. Reactive oxygen species as regulators of MDSC-mediated immune suppression. Front Immunol. 2018;9:2499.","journal-title":"Front Immunol"},{"issue":"2","key":"2572_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020210","volume":"13","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers (Basel). 2021;13(2):210.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2572_CR129","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.gastro.2020.10.036","volume":"160","author":"W Kim","year":"2021","unstructured":"Kim W, Chu TH, Nienh\u00fcser H, et al. PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice. Gastroenterology. 2021;160(3):781\u201396.","journal-title":"Gastroenterology"},{"issue":"9","key":"2572_CR130","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00262-018-2177-1","volume":"67","author":"Y Deng","year":"2018","unstructured":"Deng Y, Yang J, Luo F, et al. mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells. Cancer Immunol Immunother. 2018;67(9):1355\u201364.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2572_CR131","doi-asserted-by":"publisher","first-page":"e2779","DOI":"10.1038\/cddis.2017.192","volume":"8","author":"SL Jian","year":"2017","unstructured":"Jian SL, Chen WW, Su YC, et al. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. Cell Death Dis. 2017;8(5):e2779.","journal-title":"Cell Death Dis"},{"key":"2572_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165845","author":"A Bleve","year":"2020","unstructured":"Bleve A, Durante B, Sica A, Consonni FM. Lipid metabolism and cancer immunotherapy: immunosuppressive myeloid cells at the crossroad. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21165845.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2572_CR133","doi-asserted-by":"publisher","first-page":"794","DOI":"10.4049\/jimmunol.1202088","volume":"190","author":"L Wang","year":"2013","unstructured":"Wang L, Chang EWY, Wong SC, Ong S-M, Chong DQY, Ling KL. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8\/A9 proinflammatory proteins. J Immunol. 2013;190(2):794\u2013804.","journal-title":"J Immunol"},{"issue":"8","key":"2572_CR134","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.ccell.2025.06.006","volume":"43","author":"J Qian","year":"2025","unstructured":"Qian J, Ma C, Waterbury QT, et al. A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. Cancer Cell. 2025;43(8):1512-1529.e1511.","journal-title":"Cancer Cell"},{"issue":"10","key":"2572_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05320-8","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Wang X, Wang X, Xu M, Sheng W. The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer. Cell Death Dis. 2022;13(10):874.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2572_CR136","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3892\/etm_00000086","volume":"1","author":"Y Fuyuhiro","year":"2010","unstructured":"Fuyuhiro Y, Yashiro M, Noda S, et al. Myofibroblasts are associated with the progression of scirrhous gastric carcinoma. Exp Ther Med. 2010;1(4):547\u201351.","journal-title":"Exp Ther Med"},{"issue":"7","key":"2572_CR137","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/bjc.2011.330","volume":"105","author":"Y Fuyuhiro","year":"2011","unstructured":"Fuyuhiro Y, Yashiro M, Noda S, et al. Upregulation of cancer-associated myofibroblasts by TGF-\u03b2 from scirrhous gastric carcinoma cells. Br J Cancer. 2011;105(7):996\u20131001.","journal-title":"Br J Cancer"},{"issue":"2","key":"2572_CR138","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","volume":"19","author":"M Quante","year":"2011","unstructured":"Quante M, Tu SP, Tomita H, et al. . Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19(2):257\u201372.","journal-title":"Cancer Cell"},{"issue":"6","key":"2572_CR139","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4132\/KoreanJPathol.2013.47.6.507","volume":"47","author":"EK Kim","year":"2013","unstructured":"Kim EK, Kim HJ, Yang YI, et al. Endogenous gastric-resident mesenchymal stem cells contribute to formation of cancer stroma and progression of gastric cancer. Korean J Pathol. 2013;47(6):507\u201318.","journal-title":"Korean J Pathol"},{"issue":"6","key":"2572_CR140","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1038\/cddis.2014.263","volume":"5","author":"Q Zhu","year":"2014","unstructured":"Zhu Q, Zhang X, Zhang L, et al. The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death Dis. 2014;5(6):e1295.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2572_CR141","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579\u201396.","journal-title":"J Exp Med"},{"issue":"1","key":"2572_CR142","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12943-023-01876-x","volume":"22","author":"C Ma","year":"2023","unstructured":"Ma C, Yang C, Peng A, et al. Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment. Mol Cancer. 2023;22(1):170.","journal-title":"Mol Cancer"},{"issue":"10","key":"2572_CR143","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.7150\/jca.49707","volume":"12","author":"Y Qin","year":"2021","unstructured":"Qin Y, Wang F, Ni H, et al. Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis. J Cancer. 2021;12(10):3011.","journal-title":"J Cancer"},{"issue":"4","key":"2572_CR144","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41568-023-00549-7","volume":"23","author":"M Tsoumakidou","year":"2023","unstructured":"Tsoumakidou M. The advent of immune stimulating CAFs in cancer. Nat Rev Cancer. 2023;23(4):258\u201369.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2572_CR145","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41467-025-57465-7","volume":"16","author":"J Song","year":"2025","unstructured":"Song J, Wei R, Liu C, et al. Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response. Nat Commun. 2025;16(1):2175.","journal-title":"Nat Commun"},{"issue":"12","key":"2572_CR146","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrm3902","volume":"15","author":"JK Mouw","year":"2014","unstructured":"Mouw JK, Ou G, Weaver VM. Extracellular matrix assembly: a multiscale deconstruction. Nat Rev Mol Cell Biol. 2014;15(12):771\u201385.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2572_CR147","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12967-025-06070-9","volume":"23","author":"Y Yang","year":"2025","unstructured":"Yang Y, Sun H, Yu H, et al. Tumor-associated-fibrosis and active collagen-CD44 axis characterize a poor-prognosis subtype of gastric cancer and contribute to tumor immunosuppression. J Transl Med. 2025;23(1):123.","journal-title":"J Transl Med"},{"issue":"2","key":"2572_CR148","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10120-015-0510-3","volume":"19","author":"H Kasashima","year":"2016","unstructured":"Kasashima H, Yashiro M, Kinoshita H, et al. Lysyl oxidase is associated with the epithelial-mesenchymal transition of gastric cancer cells in hypoxia. Gastric Cancer. 2016;19(2):431\u201342.","journal-title":"Gastric Cancer"},{"issue":"5","key":"2572_CR149","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ijc.30801","volume":"141","author":"X Wang","year":"2017","unstructured":"Wang X, Zhou Q, Yu Z, et al. Cancer-associated fibroblast-derived lumican promotes gastric cancer progression via the integrin \u03b21-FAK signaling pathway. Int J Cancer. 2017;141(5):998\u20131010.","journal-title":"Int J Cancer"},{"issue":"1","key":"2572_CR150","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41551-020-00657-x","volume":"5","author":"M Jang","year":"2021","unstructured":"Jang M, An J, Oh SW, et al. Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer. Nat Biomed Eng. 2021;5(1):114\u201323.","journal-title":"Nat Biomed Eng"},{"issue":"8","key":"2572_CR151","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.7150\/jca.18466","volume":"8","author":"ZH Zhou","year":"2017","unstructured":"Zhou ZH, Ji CD, Xiao HL, Zhao HB, Cui YH, Bian XW. Reorganized collagen in the tumor microenvironment of gastric cancer and its association with prognosis. J Cancer. 2017;8(8):1466\u201376.","journal-title":"J Cancer"},{"key":"2572_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.760534","volume":"12","author":"L Wang","year":"2021","unstructured":"Wang L, Cao S, Zhai R, Zhao Y, Song G. Systematic analysis of expression and prognostic values of lysyl oxidase family in gastric cancer. Front Genet. 2021;12:760534.","journal-title":"Front Genet"},{"key":"2572_CR153","doi-asserted-by":"publisher","first-page":"753330","DOI":"10.3389\/fonc.2021.753330","volume":"11","author":"Z Yang","year":"2021","unstructured":"Yang Z, Xue F, Li M, et al. Extracellular matrix characterization in gastric cancer helps to predict prognosis and chemotherapy response. Front Oncol. 2021;11:753330.","journal-title":"Front Oncol"},{"issue":"3","key":"2572_CR154","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4103\/0973-1482.119302","volume":"9","author":"CL Sampieri","year":"2013","unstructured":"Sampieri CL, Le\u00f3n-C\u00f3rdoba K, Remes-Troche JM. Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers. J Cancer Res Ther. 2013;9(3):356\u201363.","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"2572_CR155","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10120-013-0302-6","volume":"17","author":"K Sentani","year":"2014","unstructured":"Sentani K, Matsuda M, Oue N, et al. Clinicopathological significance of MMP-7, laminin \u03b32 and EGFR expression at the invasive front of gastric carcinoma. Gastric Cancer. 2014;17(3):412\u201322.","journal-title":"Gastric Cancer"},{"issue":"3","key":"2572_CR156","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/jcb.27681","volume":"120","author":"M Najafi","year":"2019","unstructured":"Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem. 2019;120(3):2782\u201390.","journal-title":"J Cell Biochem"},{"key":"2572_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091636","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Miyazaki M. Heterocellular adhesion in cancer invasion and metastasis: interactions between cancer cells and cancer-associated fibroblasts. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16091636.","journal-title":"Cancers"},{"key":"2572_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020394","author":"AM Moreira","year":"2020","unstructured":"Moreira AM, Pereira J, Melo S, et al. The extracellular matrix: an accomplice in gastric cancer development and progression. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9020394.","journal-title":"Cells"},{"key":"2572_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102113","volume":"49","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhao Y, Chen X. Collagen extracellular matrix promotes gastric cancer immune evasion by activating IL4I1-AHR signaling. Transl Oncol. 2024;49:102113.","journal-title":"Transl Oncol"},{"issue":"4","key":"2572_CR160","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/j.2040-4603.2014.tb00587.x","volume":"4","author":"KN Browning","year":"2014","unstructured":"Browning KN, Travagli RA. Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. Compr Physiol. 2014;4(4):1339\u201368.","journal-title":"Compr Physiol"},{"issue":"7","key":"2572_CR161","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrgastro.2016.76","volume":"13","author":"RA Travagli","year":"2016","unstructured":"Travagli RA, Anselmi L. Vagal neurocircuitry and its influence on gastric motility. Nat Rev Gastroenterol Hepatol. 2016;13(7):389\u2013401.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8059","key":"2572_CR162","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41586-025-08591-1","volume":"640","author":"X Zhi","year":"2025","unstructured":"Zhi X, Wu F, Qian J, et al. Nociceptive neurons promote gastric tumour progression via a CGRP-RAMP1 axis. Nature. 2025;640(8059):802\u201310.","journal-title":"Nature"},{"issue":"1","key":"2572_CR163","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2016.11.005","volume":"31","author":"Y Hayakawa","year":"2017","unstructured":"Hayakawa Y, Sakitani K, Konishi M, et al. Nerve growth factor promotes gastric tumorigenesis through aberrant cholinergic signaling. Cancer Cell. 2017;31(1):21\u201334.","journal-title":"Cancer Cell"},{"issue":"1","key":"2572_CR164","volume":"1873","author":"K Wang","year":"2020","unstructured":"Wang K, Zhao XH, Liu J, Zhang R, Li JP. Nervous system and gastric cancer. Biochimica et Biophysica Acta (BBA). 2020;1873(1):188313.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"250","key":"2572_CR165","doi-asserted-by":"publisher","first-page":"250ra115","DOI":"10.1126\/scitranslmed.3009569","volume":"6","author":"CM Zhao","year":"2014","unstructured":"Zhao CM, Hayakawa Y, Kodama Y, et al. Denervation suppresses gastric tumorigenesis. Sci Transl Med. 2014;6(250):250ra115.","journal-title":"Sci Transl Med"},{"issue":"11","key":"2572_CR166","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41419-019-2030-2","volume":"10","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhang Y, He Z, et al. Chronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2. Cell Death Dis. 2019;10(11):788.","journal-title":"Cell Death Dis"},{"key":"2572_CR167","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00432-016-2278-1","volume":"143","author":"M Coelho","year":"2017","unstructured":"Coelho M, Soares-Silva C, Brand\u00e3o D, Marino F, Cosentino M, Ribeiro L. \u03b2-adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. J Cancer Res Clin Oncol. 2017;143:275\u201391.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2572_CR168","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.3892\/mmr.2015.3595","volume":"18","author":"Y Wang","year":"2018","unstructured":"Wang Y, Cui P, Liu J, Wu H, Ma J. Aclidinium bromide inhibits the growth and metastasis of gastric cancer MKN-28 cells via the PI3K signaling pathway. Mol Med Rep. 2018;18(2):2263\u20138.","journal-title":"Mol Med Rep"},{"issue":"13","key":"2572_CR169","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.12998\/wjcc.v7.i13.1554","volume":"7","author":"YZ Di","year":"2019","unstructured":"Di YZ, Han BS, Di JM, Liu WY, Tang Q. Role of the brain-gut axis in gastrointestinal cancer. World J Clin Cases. 2019;7(13):1554.","journal-title":"World J Clin Cases"},{"issue":"4","key":"2572_CR170","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/08923973.2015.1059442","volume":"37","author":"Y Liu","year":"2015","unstructured":"Liu Y, Wei J, Guo G, Zhou J. Norepinephrine-induced myeloid-derived suppressor cells block T-cell responses via generation of reactive oxygen species. Immunopharmacol Immunotoxicol. 2015;37(4):359\u201365.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"12","key":"2572_CR171","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1002\/ijc.28622","volume":"134","author":"PL Raber","year":"2014","unstructured":"Raber PL, Thevenot P, Sierra R, et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer. 2014;134(12):2853\u201364.","journal-title":"Int J Cancer"},{"issue":"6\u20137","key":"2572_CR172","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3109\/08820139.2012.680634","volume":"41","author":"P Raber","year":"2012","unstructured":"Raber P, Ochoa AC, Rodr\u00edguez PC. Metabolism of l-arginine by myeloid-derived suppressor cells in cancer: mechanisms of t cell suppression and therapeutic perspectives. Immunol Invest. 2012;41(6\u20137):614\u201334.","journal-title":"Immunol Invest"},{"issue":"6","key":"2572_CR173","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrc.2016.38","volume":"16","author":"M Amit","year":"2016","unstructured":"Amit M, Na\u2019ara S, Gil Z. Mechanisms of cancer dissemination along nerves. Nat Rev Cancer. 2016;16(6):399\u2013408.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2572_CR174","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1053\/j.gastro.2014.09.040","volume":"147","author":"M Neunlist","year":"2014","unstructured":"Neunlist M, Rolli-Derkinderen M, Latorre R, et al. Enteric glial cells: recent developments and future directions. Gastroenterology. 2014;147(6):1230\u20137.","journal-title":"Gastroenterology"},{"key":"2572_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00164","volume":"9","author":"G Qiao","year":"2018","unstructured":"Qiao G, Chen M, Bucsek MJ, Repasky EA, Hylander BL. Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response. Front Immunol. 2018;9:164.","journal-title":"Front Immunol"},{"issue":"11","key":"2572_CR176","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1158\/2326-6066.CIR-18-0833","volume":"7","author":"C Daher","year":"2019","unstructured":"Daher C, Vimeux L, Stoeva R, et al. Blockade of \u03b2-adrenergic receptors improves CD8(+) T-cell priming and cancer vaccine efficacy. Cancer Immunol Res. 2019;7(11):1849\u201363.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2572_CR177","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1038\/s41598-025-87492-9","volume":"15","author":"T Itami","year":"2025","unstructured":"Itami T, Kurokawa Y, Hagi T, et al. Sympathetic innervation induced by nerve growth factor promotes malignant transformation in gastric cancer. Sci Rep. 2025;15(1):3824.","journal-title":"Sci Rep"},{"issue":"9","key":"2572_CR178","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/jclinpath-2019-206372","volume":"73","author":"B Zhao","year":"2020","unstructured":"Zhao B, Lv W, Mei D, et al. Perineural invasion as a predictive factor for survival outcome in gastric cancer patients: a systematic review and meta-analysis. J Clin Pathol. 2020;73(9):544\u201351.","journal-title":"J Clin Pathol"},{"issue":"8","key":"2572_CR179","doi-asserted-by":"publisher","first-page":"116059","DOI":"10.1016\/j.celrep.2025.116059","volume":"44","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen J, Zhou Y, et al. Neuroimmune axis in gastrointestinal cancers: from mechanisms to therapeutic breakthrough. Cell Rep. 2025;44(8):116059.","journal-title":"Cell Rep"},{"key":"2572_CR180","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00262-002-0300-8","volume":"51","author":"F Entschladen","year":"2002","unstructured":"Entschladen F, Lang K, Drell TL, Joseph J, Zaenker KS. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother. 2002;51:467\u201382.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2572_CR181","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-025-10241-x","volume":"44","author":"A Sattler","year":"2025","unstructured":"Sattler A, Korzun T, Gupta K, Diba P, Kyprianou N, Eksi SE. Sympathetic nerve signaling rewires the tumor microenvironment: a shift in \u201cmicroenvironmental-ity.\u201d Cancer Metastasis Rev. 2025;44(1):25.","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"2572_CR182","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41568-024-00681-y","volume":"24","author":"T Karakousi","year":"2024","unstructured":"Karakousi T, Mudianto T, Lund AW. Lymphatic vessels in the age of cancer immunotherapy. Nat Rev Cancer. 2024;24(6):363\u201381.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2572_CR183","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.18632\/oncotarget.23526","volume":"9","author":"L Liang","year":"2018","unstructured":"Liang L, Huang WT, He RQ, et al. A meta-analysis of the lymphatic microvessel density and survival in gastric cancer with 1809 cases. Oncotarget. 2018;9(4):5406\u201315.","journal-title":"Oncotarget"},{"issue":"1","key":"2572_CR184","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s40001-023-01298-x","volume":"28","author":"P Liu","year":"2023","unstructured":"Liu P, Ding P, Sun C, et al. Lymphangiogenesis in gastric cancer: function and mechanism. Eur J Med Res. 2023;28(1):405.","journal-title":"Eur J Med Res"},{"issue":"12","key":"2572_CR185","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ejso.2010.09.002","volume":"36","author":"FH Han","year":"2010","unstructured":"Han FH, Li HM, Zheng DH, He YL, Zhan WH. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol (EJSO). 2010;36(12):1172\u20139.","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"4","key":"2572_CR186","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3346\/jkms.2008.23.4.592","volume":"23","author":"JH Choi","year":"2008","unstructured":"Choi JH, Oh YH, Park YW, Baik HK, Lee YY, Kim IS. Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma. J Korean Med Sci. 2008;23(4):592\u20137.","journal-title":"J Korean Med Sci"},{"issue":"Suppl 4","key":"2572_CR187","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/jgh.12733","volume":"29","author":"J Rudno-Rudzi\u0144ska","year":"2014","unstructured":"Rudno-Rudzi\u0144ska J, Donizy P, Frejlich E, et al. Lymphangiogenesis in early and advanced gastric cancer: is there any difference? J Gastroenterol Hepatol. 2014;29(Suppl 4):107\u201311.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"2572_CR188","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5230\/jgc.2014.14.3.196","volume":"14","author":"S Taghizadeh","year":"2014","unstructured":"Taghizadeh S, Sankian M, Ajami A, et al. Expression levels of vascular endothelial growth factors a and c in patients with peptic ulcers and gastric cancer. J Gastric Cancer. 2014;14(3):196\u2013203.","journal-title":"J Gastric Cancer"},{"issue":"4","key":"2572_CR189","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41419-022-04821-w","volume":"13","author":"L Zhao","year":"2022","unstructured":"Zhao L, Liu Y, Zhang S, et al. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. Cell Death Dis. 2022;13(4):378.","journal-title":"Cell Death Dis"},{"key":"2572_CR190","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/OTT.S189687","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhang Z, Wang J, et al. Metabolic reprogramming results in abnormal glycolysis in gastric cancer: a review. Onco Targets Ther. 2019;12:1195\u2013204.","journal-title":"Onco Targets Ther"},{"key":"2572_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1628937","volume":"16","author":"Z Shan","year":"2025","unstructured":"Shan Z, Liu Y. Harnessing glycolysis in gastric cancer: molecular targets, therapeutic strategies, and clinical horizons. Front Immunol. 2025;16:1628937.","journal-title":"Front Immunol"},{"issue":"1","key":"2572_CR192","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12935-023-03162-8","volume":"23","author":"H Yang","year":"2023","unstructured":"Yang H, Yang S, He J, et al. Glucose transporter 3 (GLUT3) promotes lactylation modifications by regulating lactate dehydrogenase A (LDHA) in gastric cancer. Cancer Cell Int. 2023;23(1):303.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"2572_CR193","doi-asserted-by":"publisher","first-page":"2263936","DOI":"10.1080\/19490976.2023.2263936","volume":"15","author":"JM Noto","year":"2023","unstructured":"Noto JM, Piazuelo MB, Romero-Gallo J, et al. Targeting hypoxia-inducible factor-1 alpha suppresses Helicobacter pylori-induced gastric injury via attenuation of both cag-mediated microbial virulence and proinflammatory host responses. Gut microbes. 2023;15(2):2263936.","journal-title":"Gut microbes"},{"issue":"3","key":"2572_CR194","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s12276-024-01180-8","volume":"56","author":"T Bae","year":"2024","unstructured":"Bae T, Hallis SP, Kwak MK. Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. Exp Mol Med. 2024;56(3):501\u201314.","journal-title":"Exp Mol Med"},{"issue":"12","key":"2572_CR195","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1002\/cam4.1820","volume":"7","author":"Y Feng","year":"2018","unstructured":"Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018;7(12):6124\u201336.","journal-title":"Cancer Med"},{"key":"2572_CR196","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.2147\/IJGM.S353592","volume":"15","author":"Q Tao","year":"2022","unstructured":"Tao Q, Li X, Zhu T, et al. Lactate transporter SLC16A3 (MCT4) as an onco-immunological biomarker associating tumor microenvironment and immune responses in lung cancer. Int J Gen Med. 2022;15:4465\u201374.","journal-title":"Int J Gen Med"},{"issue":"1","key":"2572_CR197","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12967-025-06279-8","volume":"23","author":"T Jiang","year":"2025","unstructured":"Jiang T, Zhang J, Zhao S, et al. MCT4: a key player influencing gastric cancer metastasis and participating in the regulation of the metastatic immune microenvironment. J Transl Med. 2025;23(1):276.","journal-title":"J Transl Med"},{"issue":"3","key":"2572_CR198","doi-asserted-by":"publisher","first-page":"e91068","DOI":"10.1371\/journal.pone.0091068","volume":"9","author":"X Sun","year":"2014","unstructured":"Sun X, Sun Z, Zhu Z, et al. Clinicopathological significance and prognostic value of lactate dehydrogenase A expression in gastric cancer patients. PLoS One. 2014;9(3):e91068.","journal-title":"PLoS One"},{"key":"2572_CR199","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113244","author":"R P\u00e9rez-Tom\u00e1s","year":"2020","unstructured":"P\u00e9rez-Tom\u00e1s R, P\u00e9rez-Guill\u00e9n I. Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12113244.","journal-title":"Cancers"},{"issue":"3","key":"2572_CR200","doi-asserted-by":"publisher","first-page":"e0245075","DOI":"10.1371\/journal.pone.0245075","volume":"16","author":"KW Min","year":"2021","unstructured":"Min KW, Kim DH, Son BK, et al. High SLC2A1 expression associated with suppressing CD8 T cells and B cells promoted cancer survival in gastric cancer. PLoS One. 2021;16(3):e0245075.","journal-title":"PLoS One"},{"issue":"5","key":"2572_CR201","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","volume":"107","author":"E Gottfried","year":"2006","unstructured":"Gottfried E, Kunz-Schughart LA, Ebner S, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107(5):2013\u201321.","journal-title":"Blood"},{"key":"2572_CR202","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218363","author":"JX Wang","year":"2020","unstructured":"Wang JX, Choi SYC, Niu X, et al. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21218363.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2572_CR203","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162(6):1229\u201341.","journal-title":"Cell"},{"key":"2572_CR204","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.691134","volume":"12","author":"I Manoharan","year":"2021","unstructured":"Manoharan I, Prasad PD, Thangaraju M, Manicassamy S. Lactate-dependent regulation of immune responses by dendritic cells and macrophages. Front Immunol. 2021;12:691134.","journal-title":"Front Immunol"},{"issue":"6","key":"2572_CR205","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.3748\/wjg.v22.i6.2046","volume":"22","author":"LW Yuan","year":"2016","unstructured":"Yuan LW, Yamashita H, Seto Y. Glucose metabolism in gastric cancer: the cutting-edge. World J Gastroenterol. 2016;22(6):2046\u201359.","journal-title":"World J Gastroenterol"},{"key":"2572_CR206","doi-asserted-by":"publisher","first-page":"648706","DOI":"10.3389\/fonc.2021.648706","volume":"11","author":"B Chen","year":"2021","unstructured":"Chen B, Cai T, Huang C, et al. G6PD-NF-\u03baB-HGF signal in gastric cancer-associated mesenchymal stem cells promotes the proliferation and metastasis of gastric cancer cells by upregulating the expression of HK2. Front Oncol. 2021;11:648706.","journal-title":"Front Oncol"},{"issue":"7851","key":"2572_CR207","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson MJ, Vignali PDA, Mullett SJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591(7851):645\u201351.","journal-title":"Nature"},{"key":"2572_CR208","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175897","author":"J Zhou","year":"2024","unstructured":"Zhou J, Gu J, Qian Q, et al. Lactate supports Treg function and immune balance via MGAT1 effects on N-glycosylation in the mitochondria. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI175897.","journal-title":"J Clin Invest"},{"issue":"30","key":"2572_CR209","doi-asserted-by":"publisher","first-page":"30102","DOI":"10.18632\/oncotarget.4945","volume":"6","author":"D Catanzaro","year":"2015","unstructured":"Catanzaro D, Gaude E, Orso G, et al. Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death. Oncotarget. 2015;6(30):30102\u201314.","journal-title":"Oncotarget"},{"key":"2572_CR210","doi-asserted-by":"publisher","DOI":"10.3390\/life12020271","author":"J Song","year":"2022","unstructured":"Song J, Sun H, Zhang S, Shan C. The multiple roles of Glucose-6-phosphate dehydrogenase in tumorigenesis and cancer chemoresistance. Life. 2022. https:\/\/doi.org\/10.3390\/life12020271.","journal-title":"Life"},{"issue":"1","key":"2572_CR211","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1049-7","volume":"38","author":"J Pan","year":"2019","unstructured":"Pan J, Fan Z, Wang Z, et al. CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT\/GSK-3\u03b2\/\u03b2-catenin pathway. J Exp Clin Cancer Res. 2019;38(1):52.","journal-title":"J Exp Clin Cancer Res"},{"issue":"18","key":"2572_CR212","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.7150\/thno.34024","volume":"9","author":"M Jiang","year":"2019","unstructured":"Jiang M, Wu N, Xu B, et al. Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Theranostics. 2019;9(18):5359\u201373.","journal-title":"Theranostics"},{"key":"2572_CR213","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091430","author":"S Koizume","year":"2016","unstructured":"Koizume S, Miyagi Y. Lipid droplets: a key cellular organelle associated with cancer cell survival under normoxia and hypoxia. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17091430.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2572_CR214","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2572_CR215","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.21037\/tcr-21-655","volume":"10","author":"MY Cui","year":"2021","unstructured":"Cui MY, Yi X, Zhu DX, Wu J. Aberrant lipid metabolism reprogramming and immune microenvironment for gastric cancer: a literature review. Transl Cancer Res. 2021;10(8):3829\u201342.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"2572_CR216","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13045-021-01200-4","volume":"14","author":"W Yu","year":"2021","unstructured":"Yu W, Lei Q, Yang L, et al. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J Hematol Oncol. 2021;14(1):187.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2572_CR217","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2326-6066.CIR-19-0702","volume":"8","author":"R Lin","year":"2020","unstructured":"Lin R, Zhang H, Yuan Y, et al. Fatty acid oxidation controls CD8(+) tissue-resident memory T-cell survival in gastric adenocarcinoma. Cancer Immunol Res. 2020;8(4):479\u201392.","journal-title":"Cancer Immunol Res"},{"issue":"7644","key":"2572_CR218","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature21379","volume":"543","author":"Y Pan","year":"2017","unstructured":"Pan Y, Tian T, Park CO, et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature. 2017;543(7644):252\u20136","journal-title":"Nature"},{"issue":"11","key":"2572_CR219","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1111\/cas.14616","volume":"111","author":"Q Luo","year":"2020","unstructured":"Luo Q, Zheng N, Jiang L, et al. Lipid accumulation in macrophages confers protumorigenic polarization and immunity in gastric cancer. Cancer Sci. 2020;111(11):4000\u201311.","journal-title":"Cancer Sci"},{"issue":"8","key":"2572_CR220","doi-asserted-by":"publisher","first-page":"e1386","DOI":"10.1002\/ctm2.1386","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Sun J, Zeng Z, et al. Tumour-associated macrophages in gastric cancer: from function and mechanism to application. Clin Transl Med. 2023;13(8):e1386.","journal-title":"Clin Transl Med"},{"issue":"11","key":"2572_CR221","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","volume":"3","author":"F Hossain","year":"2015","unstructured":"Hossain F, Al-Khami AA, Wyczechowska D, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res. 2015;3(11):1236\u201347.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2572_CR222","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"HR Jin","year":"2023","unstructured":"Jin HR, Wang J, Wang ZJ, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16(1):103.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2572_CR223","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40364-024-00588-8","volume":"12","author":"Y Shan","year":"2024","unstructured":"Shan Y, Xie T, Sun Y, et al. Lipid metabolism in tumor-infiltrating regulatory T cells: perspective to precision immunotherapy. Biomark Res. 2024;12(1):41.","journal-title":"Biomark Res"},{"key":"2572_CR224","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-3-030-65768-0_2","volume-title":"The Heterogeneity of Cancer Metabolism","author":"T Li","year":"2021","unstructured":"Li T, Copeland C, Le A. Glutamine metabolism in cancer. In: The Heterogeneity of Cancer Metabolism. Springer International Publishing Cham; 2021. p. 17\u201338."},{"key":"2572_CR225","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1201297","volume":"13","author":"H Li","year":"2023","unstructured":"Li H, Wu Z, Zhang Y, Lu X, Miao L. Glutamine metabolism genes prognostic signature for stomach adenocarcinoma and immune infiltration: potential biomarkers for predicting overall survival. Front Oncol. 2023;13:1201297.","journal-title":"Front Oncol"},{"issue":"8","key":"2572_CR226","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41419-023-06049-8","volume":"14","author":"L Fang","year":"2023","unstructured":"Fang L, Huang H, Lv J, et al. m5C-methylated lncRNA NR_033928 promotes gastric cancer proliferation by stabilizing GLS mRNA to promote glutamine metabolism reprogramming. Cell Death Dis. 2023;14(8):520.","journal-title":"Cell Death Dis"},{"key":"2572_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103614","author":"J Xiong","year":"2021","unstructured":"Xiong J, Wang N, Zhong H-J, et al. SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential. EBioMedicine. 2021. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103614.","journal-title":"EBioMedicine"},{"issue":"8","key":"2572_CR228","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/cac2.12459","volume":"43","author":"X Hu","year":"2023","unstructured":"Hu X, Ma Z, Xu B, et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer Commun. 2023;43(8):909\u201337.","journal-title":"Cancer Commun"},{"issue":"1","key":"2572_CR229","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000523750","volume":"90","author":"QT Pham","year":"2023","unstructured":"Pham QT, Taniyama D, Akabane S, et al. Essential roles of TDO2 in gastric cancer: TDO2 is associated with cancer progression, patient survival, PD-L1 expression, and cancer stem cells. Pathobiology. 2023;90(1):44\u201355.","journal-title":"Pathobiology"},{"issue":"8","key":"2572_CR230","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083706","volume":"26","author":"K O\u017cga","year":"2025","unstructured":"O\u017cga K, Stepuch P, Maciejewski R, Sadok I. Promising gastric cancer biomarkers\u2014focus on tryptophan metabolism via the kynurenine pathway. Int J Mol Sci. 2025;26(8):3706.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2572_CR231","doi-asserted-by":"publisher","first-page":"e002840","DOI":"10.1136\/jitc-2021-002840","volume":"9","author":"R Qin","year":"2021","unstructured":"Qin R, Zhao C, Wang C-J, et al. Tryptophan potentiates CD8+ T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. J Immunother Cancer. 2021;9(7):e002840.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2572_CR232","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1089\/dna.2021.0936","volume":"41","author":"D Wu","year":"2022","unstructured":"Wu D, Wang Z. Gastric cancer cell-derived kynurenines hyperactive regulatory T cells to promote chemoresistance via the IL-10\/STAT3\/BCL2 signaling pathway. DNA Cell Biol. 2022;41(4):447\u201355.","journal-title":"DNA Cell Biol"},{"issue":"1","key":"2572_CR233","doi-asserted-by":"publisher","first-page":"8056","DOI":"10.1038\/s41598-020-64841-4","volume":"10","author":"W Ren","year":"2020","unstructured":"Ren W, Zhang X, Li W, et al. Circulating and tumor-infiltrating arginase 1-expressing cells in gastric adenocarcinoma patients were mainly immature and monocytic myeloid-derived suppressor cells. Sci Rep. 2020;10(1):8056.","journal-title":"Sci Rep"},{"issue":"4","key":"2572_CR234","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41577-024-01098-2","volume":"25","author":"S Can\u00e8","year":"2025","unstructured":"Can\u00e8 S, Geiger R, Bronte V. The roles of arginases and arginine in immunity. Nat Rev Immunol. 2025;25(4):266\u201384.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2572_CR235","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00726-019-02719-0","volume":"52","author":"YL Latour","year":"2020","unstructured":"Latour YL, Gobert AP, Wilson KT. The role of polyamines in the regulation of macrophage polarization and function. Amino Acids. 2020;52(2):151\u201360.","journal-title":"Amino Acids"},{"issue":"6","key":"2572_CR236","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ccell.2025.03.015","volume":"43","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Zhou Z, Du X, et al. Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion. Cancer Cell. 2025;43(6):1045\u201360.","journal-title":"Cancer Cell"},{"key":"2572_CR237","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2025.10.030","author":"G Cai","year":"2025","unstructured":"Cai G, Zhang Z, Zhong L, et al. UMP functions as an endogenous regulator of NR4A1 to control gastric cancer progression. Mol Cell. 2025. https:\/\/doi.org\/10.1016\/j.molcel.2025.10.030.","journal-title":"Mol Cell"},{"issue":"5","key":"2572_CR238","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023;23(5):275\u201394.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2572_CR239","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12935-021-02385-x","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu Z, Tan J, Zhuang Y, et al. Identification of crucial genes of pyrimidine metabolism as biomarkers for gastric cancer prognosis. Cancer Cell Int. 2021;21(1):668.","journal-title":"Cancer Cell Int"},{"issue":"13","key":"2572_CR240","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-21-4383","volume":"28","author":"J Wang","year":"2022","unstructured":"Wang J, Kunzke T, Prade VM, et al. Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients. Clin Cancer Res. 2022;28(13):2865\u201377.","journal-title":"Clin Cancer Res"},{"key":"2572_CR241","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2021.08.006","volume":"157","author":"X He","year":"2021","unstructured":"He X, Gu Y, Cao Y, et al. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. Eur J Cancer. 2021;157:114\u201323.","journal-title":"Eur J Cancer"},{"key":"2572_CR242","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1027838","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Du L, Chen X. Adenosine signaling: optimal target for gastric cancer immunotherapy. Front Immunol. 2022;13:1027838.","journal-title":"Front Immunol"},{"issue":"4","key":"2572_CR243","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.826","volume":"11","author":"H Ye","year":"2023","unstructured":"Ye H, Zhao J, Xu X, Zhang D, Shen H, Wang S. Role of adenosine A2a receptor in cancers and autoimmune diseases. Immunity Inflamm Dis. 2023;11(4):e826.","journal-title":"Immunity Inflamm Dis"},{"issue":"13","key":"2572_CR244","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3390\/cells11132020","volume":"11","author":"MB Ahmed","year":"2022","unstructured":"Ahmed MB, Alghamdi AAA, Islam SU, Lee J-S, Lee Y-S. cAMP signaling in cancer: a PKA-CREB and EPAC-centric approach. Cells. 2022;11(13):2020.","journal-title":"Cells"},{"key":"2572_CR245","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.87292.3","author":"NJ Mullen","year":"2024","unstructured":"Mullen NJ, Shukla SK, Thakur R, et al. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. Elife. 2024. https:\/\/doi.org\/10.7554\/eLife.87292.3.","journal-title":"Elife"},{"key":"2572_CR246","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-3-030-37184-5_6","volume-title":"Tumor microenvironment: Non-hematopoietic cells","author":"K Sobierajska","year":"2020","unstructured":"Sobierajska K, Ciszewski WM, Sacewicz-Hofman I, Niewiarowska J. Endothelial cells in the tumor microenvironment. In: Tumor microenvironment: Non-hematopoietic cells. 2020. p. 71\u201386."},{"issue":"10","key":"2572_CR247","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1111\/cas.13336","volume":"108","author":"N Maishi","year":"2017","unstructured":"Maishi N, Hida K. Tumor endothelial cells accelerate tumor metastasis. Cancer Sci. 2017;108(10):1921\u20136.","journal-title":"Cancer Sci"},{"issue":"6","key":"2572_CR248","doi-asserted-by":"publisher","first-page":"R1072","DOI":"10.1152\/ajpregu.00209.2018","volume":"315","author":"L Schito","year":"2018","unstructured":"Schito L. Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment. Am J Physiol Regul Integr Comp Physiol. 2018;315(6):R1072-84.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"5","key":"2572_CR249","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/ijc.25129","volume":"127","author":"J Nakamura","year":"2010","unstructured":"Nakamura J, Kitajima Y, Kai K, et al. HIF-1\u03b1 is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. Int J Cancer. 2010;127(5):1158\u201371.","journal-title":"Int J Cancer"},{"key":"2572_CR250","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12079-016-0352-8","volume":"10","author":"CS Abhinand","year":"2016","unstructured":"Abhinand CS, Raju R, Soumya SJ, Arya PS, Sudhakaran PR. VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal. 2016;10:347\u201354.","journal-title":"J Cell Commun Signal"},{"key":"2572_CR251","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1245\/s10434-007-9596-0","volume":"15","author":"E Lieto","year":"2008","unstructured":"Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15:69\u201379.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2572_CR252","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers5010015","volume":"5","author":"Y Kitajima","year":"2013","unstructured":"Kitajima Y, Miyazaki K. The critical impact of HIF-1\u03b1 on gastric cancer biology. Cancers (Basel). 2013;5(1):15\u201326.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2572_CR253","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/1751-2980.12496","volume":"18","author":"Y Xuan","year":"2017","unstructured":"Xuan Y, Wang YN. Hypoxia\/IL-1\u03b1 axis promotes gastric cancer progression and drug resistance. J Dig Dis. 2017;18(9):511\u201320.","journal-title":"J Dig Dis"},{"issue":"2","key":"2572_CR254","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.canlet.2015.12.023","volume":"380","author":"F Shan","year":"2016","unstructured":"Shan F, Miao R, Xue K, et al. Controlling angiogenesis in gastric cancer: a systematic review of anti-angiogenic trials. Cancer Lett. 2016;380(2):598\u2013607.","journal-title":"Cancer Lett"},{"issue":"9","key":"2572_CR255","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.yexcr.2012.12.023","volume":"319","author":"M Reis","year":"2013","unstructured":"Reis M, Liebner WS. Wnt signaling in the vasculature. Exp Cell Res. 2013;319(9):1317\u201323.","journal-title":"Exp Cell Res"},{"issue":"4","key":"2572_CR256","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/bies.20736","volume":"30","author":"AF Siekmann","year":"2008","unstructured":"Siekmann AF, Covassin L, Lawson ND. Modulation of VEGF signalling output by the Notch pathway. Bioessays. 2008;30(4):303\u201313.","journal-title":"Bioessays"},{"issue":"12","key":"2572_CR257","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrc.2017.93","volume":"17","author":"MW Dewhirst","year":"2017","unstructured":"Dewhirst MW, Secomb TW. Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer. 2017;17(12):738\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2572_CR258","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2022.13489","volume":"24","author":"D Ribatti","year":"2022","unstructured":"Ribatti D. Immunosuppressive effects of vascular endothelial growth factor. Oncol Lett. 2022;24(4):1\u20136.","journal-title":"Oncol Lett"},{"issue":"7","key":"2572_CR259","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.3748\/wjg.v20.i7.1667","volume":"20","author":"HW Chung","year":"2014","unstructured":"Chung HW, Lim J-B. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol. 2014;20(7):1667.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2572_CR260","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10120-021-01270-w","volume":"25","author":"Y Yang","year":"2022","unstructured":"Yang Y, Ma Y, Yan S, et al. CAF promotes chemoresistance through NRP2 in gastric cancer. Gastric Cancer. 2022;25(3):503\u201314.","journal-title":"Gastric Cancer"},{"key":"2572_CR261","doi-asserted-by":"publisher","first-page":"1446613","DOI":"10.3389\/fimmu.2024.1446613","volume":"15","author":"H Wang","year":"2024","unstructured":"Wang H, Yang L, Chen W, et al. High-resolution subtyping of fibroblasts in gastric cancer reveals diversity among fibroblast subsets and an association between the MFAP5-fibroblast subset and immunotherapy. Front Immunol. 2024;15:1446613.","journal-title":"Front Immunol"},{"issue":"1","key":"2572_CR262","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02599-7","volume":"22","author":"B Feng","year":"2022","unstructured":"Feng B, Wu J, Shen B, Jiang F, Feng J. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures. Cancer Cell Int. 2022;22(1):166.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2572_CR263","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05939-5","volume":"22","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Xiong S, Gao J, Zhang Y, Guo E, Huang Y. C3+ cancer-associated fibroblasts promote tumor growth and therapeutic resistance in gastric cancer via activation of the NF-\u03baB signaling pathway. J Transl Med. 2024;22(1):1130.","journal-title":"J Transl Med"},{"issue":"1","key":"2572_CR264","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang L, Wan D, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"2572_CR265","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1158\/0008-5472.CAN-19-3803","volume":"80","author":"T Uchihara","year":"2020","unstructured":"Uchihara T, Miyake K, Yonemura A, et al. Extracellular vesicles from cancer-associated fibroblasts containing annexin A6 induces FAK-YAP activation by stabilizing \u03b21 integrin, enhancing drug resistance. Cancer Res. 2020;80(16):3222\u201335.","journal-title":"Cancer Res"},{"issue":"7","key":"2572_CR266","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2174\/1389450120666191127113854","volume":"21","author":"LV Spirina","year":"2020","unstructured":"Spirina LV, Avgustinovich AV, Afanas\u2019ev SG, et al. Molecular mechanism of resistance to chemotherapy in gastric cancers, the role of autophagy. Curr Drug Targets. 2020;21(7):713\u201321.","journal-title":"Curr Drug Targets"},{"issue":"6","key":"2572_CR267","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-19-0353","volume":"26","author":"P Fern\u00e1ndez-Nogueira","year":"2020","unstructured":"Fern\u00e1ndez-Nogueira P, Mancino M, Fuster G, et al. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation. Clin Cancer Res. 2020;26(6):1432\u201348.","journal-title":"Clin Cancer Res"},{"key":"2572_CR268","doi-asserted-by":"publisher","DOI":"10.3390\/biology14081067","author":"N Corro","year":"2025","unstructured":"Corro N, Alarc\u00f3n S, Astroza \u00c1, Gonz\u00e1lez-Stegmaier R, A\u00f1azco C. Mimicking gastric cancer collagen reorganization with decellularized ECM-based scaffolds. Biology. 2025. https:\/\/doi.org\/10.3390\/biology14081067.","journal-title":"Biology"},{"issue":"2","key":"2572_CR269","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7150\/thno.60540","volume":"12","author":"X Li","year":"2022","unstructured":"Li X, Sun Z, Peng G, et al. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer. Theranostics. 2022;12(2):620\u201338.","journal-title":"Theranostics"},{"issue":"1","key":"2572_CR270","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"L Pei","year":"2023","unstructured":"Pei L, Liu Y, Liu L, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):29.","journal-title":"Mol Cancer"},{"issue":"7693","key":"2572_CR271","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of t cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"key":"2572_CR272","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005543","author":"M Yi","year":"2022","unstructured":"Yi M, Wu Y, Niu M, et al. Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005543.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2572_CR273","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2189295","volume":"55","author":"D Li","year":"2023","unstructured":"Li D, Wang Y, Shi C, Fu S, Sun YF, Li C. Targeting GPC3(high) cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer. Ann Med. 2023;55(1):2189295.","journal-title":"Ann Med"},{"issue":"10","key":"2572_CR274","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41419-020-03087-4","volume":"11","author":"T Yang","year":"2020","unstructured":"Yang T, Shu X, Zhang HW, et al. Enolase 1 regulates stem cell-like properties in gastric cancer cells by stimulating glycolysis. Cell Death Dis. 2020;11(10):870.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2572_CR275","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3892\/ijo.2012.1687","volume":"42","author":"H Hur","year":"2013","unstructured":"Hur H, Xuan Y, Kim YB, et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol. 2013;42(1):44\u201354.","journal-title":"Int J Oncol"},{"key":"2572_CR276","doi-asserted-by":"publisher","first-page":"1563303","DOI":"10.3389\/fimmu.2025.1563303","volume":"16","author":"XY Gu","year":"2025","unstructured":"Gu XY, Yang JL, Lai R, et al. Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front Immunol. 2025;16:1563303.","journal-title":"Front Immunol"},{"key":"2572_CR277","doi-asserted-by":"publisher","first-page":"8203789","DOI":"10.1155\/2016\/8203789","volume":"2016","author":"QF Tang","year":"2016","unstructured":"Tang QF, Sun J, Yu H, et al. The zuo jin wan formula induces mitochondrial apoptosis of Cisplatin-resistant gastric cancer cells via Cofilin-1. Evid Based Complement Alternat Med. 2016;2016:8203789.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"23","key":"2572_CR278","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1038\/s41388-019-0747-0","volume":"38","author":"W He","year":"2019","unstructured":"He W, Liang B, Wang C, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019;38(23):4637\u201354.","journal-title":"Oncogene"},{"key":"2572_CR279","doi-asserted-by":"publisher","first-page":"216235","DOI":"10.1016\/j.canlet.2023.216235","volume":"565","author":"Z Chen","year":"2023","unstructured":"Chen Z, Xu P, Wang X, et al. MSC-NPRA loop drives fatty acid oxidation to promote stemness and chemoresistance of gastric cancer. Cancer Lett. 2023;565:216235.","journal-title":"Cancer Lett"},{"issue":"4","key":"2572_CR280","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","volume":"55","author":"J Jin","year":"2023","unstructured":"Jin J, Byun JK, Choi YK, Park KG. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023;55(4):706\u201315.","journal-title":"Exp Mol Med"},{"issue":"1","key":"2572_CR281","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12964-024-01552-7","volume":"22","author":"L Yu","year":"2024","unstructured":"Yu L, Lu J, Du W. Tryptophan metabolism in digestive system tumors: unraveling the pathways and implications. Cell Commun Signal. 2024;22(1):174.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"2572_CR282","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10038-005-0339-4","volume":"51","author":"JW Lu","year":"2006","unstructured":"Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF. Polymorphism in the 3\u2019-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet. 2006;51(3):155\u201360.","journal-title":"J Hum Genet"},{"issue":"3","key":"2572_CR283","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10120-018-0881-3","volume":"22","author":"R Mori","year":"2019","unstructured":"Mori R, Yoshida K, Futamura M, et al. The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells. Gastric Cancer. 2019;22(3):497\u2013505.","journal-title":"Gastric Cancer"},{"issue":"1","key":"2572_CR284","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","volume":"18","author":"M Shen","year":"2025","unstructured":"Shen M, Jiang X, Peng Q, et al. The cGAS-STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications. J Hematol Oncol. 2025;18(1):40.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2572_CR285","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","volume":"19","author":"J Zheng","year":"2020","unstructured":"Zheng J, Mo J, Zhu T, et al. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19(1):133.","journal-title":"Mol Cancer"},{"key":"2572_CR286","doi-asserted-by":"publisher","first-page":"11325","DOI":"10.2147\/OTT.S231846","volume":"12","author":"J Wang","year":"2019","unstructured":"Wang J, Lv B, Su Y, Wang X, Bu J, Yao L. Exosome-mediated transfer of lncRNA HOTTIP promotes cisplatin resistance in gastric cancer cells by regulating HMGA1\/miR-218 axis. Onco Targets Ther. 2019;12:11325\u201338.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2572_CR287","first-page":"326","volume":"54","author":"M Wang","year":"2019","unstructured":"Wang M, Qiu R, Yu S, et al. Paclitaxel-resistant gastric cancer MGC-803 cells promote epithelial-to-mesenchymal transition and chemoresistance in paclitaxel-sensitive cells via exosomal delivery of miR-155-5p. Int J Oncol. 2019;54(1):326\u201338.","journal-title":"Int J Oncol"},{"key":"2572_CR288","doi-asserted-by":"publisher","first-page":"618899","DOI":"10.3389\/fcell.2021.618899","volume":"9","author":"MY Sun","year":"2021","unstructured":"Sun MY, Xu B, Wu QX, et al. Cisplatin-resistant gastric cancer cells promote the chemoresistance of cisplatin-sensitive cells via the exosomal RPS3-mediated PI3K-Akt-Cofilin-1 signaling axis. Front Cell Dev Biol. 2021;9:618899.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2572_CR289","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-020-01168-8","volume":"19","author":"H Zhang","year":"2020","unstructured":"Zhang H, Deng T, Liu R, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):43.","journal-title":"Mol Cancer"},{"issue":"1","key":"2572_CR290","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13046-017-0528-y","volume":"36","author":"P Zheng","year":"2017","unstructured":"Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36(1):53.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2572_CR291","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1186\/s12967-024-05611-y","volume":"22","author":"H Li","year":"2024","unstructured":"Li H, Chen X, Zheng S, et al. The expansion of MDSCs induced by exosomal PD-L1 promotes the progression of gastric cancer. J Transl Med. 2024;22(1):821.","journal-title":"J Transl Med"},{"key":"2572_CR292","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111776","author":"M Hinata","year":"2020","unstructured":"Hinata M, Kunita A, Abe H, et al. Exosomes of Epstein-Barr virus-associated gastric carcinoma suppress dendritic cell maturation. Microorganisms. 2020. https:\/\/doi.org\/10.3390\/microorganisms8111776.","journal-title":"Microorganisms"},{"issue":"1","key":"2572_CR293","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-018-0898-6","volume":"17","author":"X Zhang","year":"2018","unstructured":"Zhang X, Shi H, Yuan X, Jiang P, Qian H, Xu W. Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol Cancer. 2018;17(1):146.","journal-title":"Mol Cancer"},{"issue":"10494","key":"2572_CR294","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, et al. Gastric cancer. Lancet. 2025;405(10494):2087\u2013102.","journal-title":"Lancet"},{"key":"2572_CR295","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002467","author":"D Zeng","year":"2021","unstructured":"Zeng D, Wu J, Luo H, et al. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002467.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2572_CR296","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-021-00249-x","volume":"6","author":"Y Lin","year":"2021","unstructured":"Lin Y, Pan X, Zhao L, et al. Immune cell infiltration signatures identified molecular subtypes and underlying mechanisms in gastric cancer. NPJ Genom Med. 2021;6(1):83.","journal-title":"NPJ Genom Med"},{"issue":"1","key":"2572_CR297","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","volume":"16","author":"D Luo","year":"2025","unstructured":"Luo D, Zhou J, Ruan S, et al. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies. Cell Death Dis. 2025;16(1):75.","journal-title":"Cell Death Dis"},{"issue":"10294","key":"2572_CR298","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"29","key":"2572_CR299","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO-25-00486","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara K, Rha SY, Wyrwicz L, et al. Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study. J Clin Oncol. 2025;43(29):3152\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2572_CR300","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang Y, Li Z, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31(4):1163\u201370.","journal-title":"Nat Med"},{"issue":"11","key":"2572_CR301","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1136\/gutjnl-2022-329134","volume":"72","author":"LL Cao","year":"2023","unstructured":"Cao LL, Lu H, Soutto M, et al. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-\u03b3 signalling. Gut. 2023;72(11):2038\u201350.","journal-title":"Gut"},{"issue":"11","key":"2572_CR302","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1158\/0008-5472.CAN-24-2697","volume":"85","author":"GT Lin","year":"2025","unstructured":"Lin GT, Yan C, Li LJ, et al. Combining apatinib and oxaliplatin remodels the immunosuppressive tumor microenvironment and sensitizes desert-type gastric cancer to immunotherapy. Cancer Res. 2025;85(11):2117\u201333.","journal-title":"Cancer Res"},{"issue":"5","key":"2572_CR303","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu RH, Ajani JA, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27(5):1058\u201368.","journal-title":"Gastric Cancer"},{"issue":"1","key":"2572_CR304","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang C, Wang Y, Chen J, et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 2023;23(1):283.","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"2572_CR305","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","volume":"36","author":"C Qi","year":"2024","unstructured":"Qi C, Chong X, Zhou T, et al. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: a retrospective study. Chin J Cancer Res. 2024;36(1):78\u201389.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"2572_CR306","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia K, Chen Y, Sun Y, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 2022;20(1):223.","journal-title":"BMC Med"},{"key":"2572_CR307","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245742","author":"R Inamoto","year":"2023","unstructured":"Inamoto R, Takahashi N, Yamada Y. Claudin18.2 in advanced gastric cancer. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15245742.","journal-title":"Cancers"},{"issue":"10","key":"2572_CR308","doi-asserted-by":"publisher","first-page":"105805","DOI":"10.1016\/j.esmoop.2025.105805","volume":"10","author":"K Yamamoto","year":"2025","unstructured":"Yamamoto K, Owaki Y, Nakayama I, et al. Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer. ESMO Open. 2025;10(10):105805.","journal-title":"ESMO Open"},{"issue":"9","key":"2572_CR309","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/2767-9764.CRC-22-0216","volume":"2","author":"H Konno","year":"2022","unstructured":"Konno H, Lin T, Wu R, et al. ZL-1211 exhibits robust antitumor activity by enhancing ADCC and activating NK cell-mediated inflammation in CLDN18.2-high and -low expressing gastric cancer models. Cancer Res Commun. 2022;2(9):937\u201350.","journal-title":"Cancer Res Commun"},{"issue":"10389","key":"2572_CR310","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","journal-title":"Lancet"},{"issue":"8","key":"2572_CR311","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","journal-title":"Nat Med"},{"issue":"4","key":"2572_CR312","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/CCO.0000000000001043","volume":"36","author":"J Lee","year":"2024","unstructured":"Lee J, Ku G. State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies. Curr Opin Oncol. 2024;36(4):326\u201331.","journal-title":"Curr Opin Oncol"},{"issue":"9742","key":"2572_CR313","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"10418","key":"2572_CR314","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208.","journal-title":"Lancet"},{"key":"2572_CR315","doi-asserted-by":"crossref","unstructured":"Sheng T, Sundar R, Srivastava S, et al. Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy. Gut.gutjnl-2024-334667.","DOI":"10.1136\/gutjnl-2024-334667"},{"issue":"1","key":"2572_CR316","doi-asserted-by":"publisher","first-page":"1981202","DOI":"10.1080\/19420862.2021.1981202","volume":"13","author":"H Xiang","year":"2021","unstructured":"Xiang H, Chan AG, Ahene A, et al. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer. MAbs. 2021;13(1):1981202.","journal-title":"MAbs"},{"issue":"1","key":"2572_CR317","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"M Katoh","year":"2016","unstructured":"Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review). Int J Mol Med. 2016;38(1):3\u201315.","journal-title":"Int J Mol Med"},{"key":"2572_CR318","doi-asserted-by":"publisher","first-page":"e2400710","DOI":"10.1200\/PO-24-00710","volume":"9","author":"SY Rha","year":"2025","unstructured":"Rha SY, Zhang Y, Elme A, et al. Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial. JCO Precis Oncol. 2025;9:e2400710.","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"2572_CR319","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780\u20137.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2572_CR320","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/S1470-2045(24)00580-1","volume":"25","author":"G Randon","year":"2024","unstructured":"Randon G, Lonardi S, Fassan M, et al. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25(12):1539\u201350.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2572_CR321","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","volume":"11","author":"BK Sah","year":"2020","unstructured":"Sah BK, Zhang B, Zhang H, et al. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020;11(1):6093.","journal-title":"Nat Commun"},{"issue":"3","key":"2572_CR322","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s12013-014-0387-5","volume":"71","author":"X-M Shen","year":"2015","unstructured":"Shen X-M, Zhou C, Lian L, Li L-Q, Li W, Tao M. Relationship between the DPD and TS mRNA expression and the response to S-1-based chemotherapy and prognosis in patients with advanced gastric cancer. Cell Biochem Biophys. 2015;71(3):1653\u201361.","journal-title":"Cell Biochem Biophys"},{"issue":"20","key":"2572_CR323","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1158\/0008-5472.CAN-19-3971","volume":"80","author":"Y-A Shen","year":"2020","unstructured":"Shen Y-A, Hong J, Asaka R, et al. Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant ovarian cancers. Cancer Res. 2020;80(20):4514\u201326.","journal-title":"Cancer Res"},{"issue":"4","key":"2572_CR324","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross MI, Demo SD, Dennison JB, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4):890\u2013901.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2572_CR325","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.esmoop.2025.104536","volume":"10","author":"MA Gouda","year":"2025","unstructured":"Gouda MA, Voss MH, Tawbi H, et al. A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 2025;10(5):104536.","journal-title":"ESMO Open"},{"issue":"2","key":"2572_CR326","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00262-024-03925-w","volume":"74","author":"L Guangzhao","year":"2025","unstructured":"Guangzhao L, Xin W, Miaoqing W, et al. IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization. Cancer Immunol Immunother. 2025;74(2):71.","journal-title":"Cancer Immunol Immunother"},{"issue":"13_Supplement","key":"2572_CR327","doi-asserted-by":"publisher","first-page":"CT153","DOI":"10.1158\/1538-7445.AM2017-CT153","volume":"77","author":"G Falchook","year":"2017","unstructured":"Falchook G, Patel M, Infante J, et al. Abstract CT153: First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640. Cancer Res. 2017;77(13_Supplement):CT153\u2013CT153.","journal-title":"Cancer Res"},{"issue":"1","key":"2572_CR328","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41420-024-01865-z","volume":"10","author":"X Chen","year":"2024","unstructured":"Chen X, Ma Z, Yi Z, et al. The effects of metabolism on the immune microenvironment in colorectal cancer. Cell Death Discov. 2024;10(1):118.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2572_CR329","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02451-0","volume":"10","author":"X Shu","year":"2025","unstructured":"Shu X, Liu S, Yang T, et al. Alpha-enolase influences ATP pool of cytoplasm and lactate homeostasis by regulating glycolysis in gastric cancer. Signal Transduct Target Ther. 2025;10(1):356.","journal-title":"Signal Transduct Target Ther"},{"key":"2572_CR330","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/5892731","volume":"2023","author":"L Li","year":"2023","unstructured":"Li L, Huang J, Huang T, et al. Effect of metformin on the prognosis of gastric cancer patients with type 2 diabetes mellitus: a meta-analysis based on retrospective cohort studies. Int J Endocrinol. 2023;2023:5892731.","journal-title":"Int J Endocrinol"},{"issue":"3","key":"2572_CR331","doi-asserted-by":"publisher","first-page":"e008923","DOI":"10.1136\/jitc-2024-008923","volume":"13","author":"Q Tang","year":"2025","unstructured":"Tang Q, Li J, Zhang L, et al. Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression. J Immunother Cancer. 2025;13(3):e008923.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2572_CR332","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1172\/JCI80009","volume":"125","author":"CJM Melief","year":"2015","unstructured":"Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401\u201312.","journal-title":"J Clin Invest"},{"issue":"4","key":"2572_CR333","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u201329.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2572_CR334","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","volume":"39","author":"K Palucka","year":"2013","unstructured":"Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38\u201348.","journal-title":"Immunity"},{"issue":"3","key":"2572_CR335","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","volume":"25","author":"Z Jahanafrooz","year":"2020","unstructured":"Jahanafrooz Z, Baradaran B, Mosafer J, et al. . Comparison of DNA and mRNA vaccines against cancer. Drug Discov Today. 2020;25(3):552\u201360.","journal-title":"Drug Discov Today"},{"issue":"4","key":"2572_CR336","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473\u201388.","journal-title":"Cancer Cell"},{"issue":"6","key":"2572_CR337","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3390\/jcm9061894","volume":"9","author":"D B\u0119bnowska","year":"2020","unstructured":"B\u0119bnowska D, Grywalska E, Nied\u017awiedzka-Rystwej P, et al. CAR-T cell therapy\u2014an overview of targets in gastric cancer. J Clin Med. 2020;9(6):1894.","journal-title":"J Clin Med"},{"issue":"9","key":"2572_CR338","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1111\/cas.14993","volume":"112","author":"F Marofi","year":"2021","unstructured":"Marofi F, Abdul-Rasheed OF, Rahman HS, et al. CAR-NK cell in cancer immunotherapy; a promising frontier. Cancer Sci. 2021;112(9):3427\u201336.","journal-title":"Cancer Sci"},{"issue":"14","key":"2572_CR339","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.7150\/ijbs.64630","volume":"17","author":"B Cao","year":"2021","unstructured":"Cao B, Liu M, Huang J, et al. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int J Biol Sci. 2021;17(14):3850.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"2572_CR340","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","volume":"20","author":"SZ Shalhout","year":"2023","unstructured":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160\u201377.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2572_CR341","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ccell.2025.03.010","volume":"43","author":"PR Lowenstein","year":"2025","unstructured":"Lowenstein PR, Varela ML, Castro MG. The discrete charm of oncolytic viruses: toward the finish line. Cancer Cell. 2025;43(4):611\u20138.","journal-title":"Cancer Cell"},{"issue":"7985","key":"2572_CR342","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling AL, Solomon IH, Landivar AM, et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023;623(7985):157\u201366.","journal-title":"Nature"},{"issue":"8062","key":"2572_CR343","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen Y, Bai X, Zhang Q, et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature. 2025;641(8062):503\u201311.","journal-title":"Nature"},{"issue":"4","key":"2572_CR344","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","volume":"188","author":"L Zhong","year":"2025","unstructured":"Zhong L, Gan L, Wang B, et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. 2025;188(4):1119-1136.e1123.","journal-title":"Cell"},{"key":"2572_CR345","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006280","author":"A Yang","year":"2023","unstructured":"Yang A, Zhang Z, Chaurasiya S, et al. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2022-006280.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2572_CR346","doi-asserted-by":"publisher","first-page":"200806","DOI":"10.1016\/j.omton.2024.200806","volume":"32","author":"M Tabuchi","year":"2024","unstructured":"Tabuchi M, Kikuchi S, Tazawa H, et al. Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer. Mol Ther Oncolytics. 2024;32(2):200806.","journal-title":"Mol Ther Oncolytics"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02572-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02572-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02572-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:06:32Z","timestamp":1772582792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02572-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":346,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2572"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02572-2","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}